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Abstract
Background: Timely diagnosis of influenza infection in patients might help reduce an-
tibiotic use during influenza seasons and, consequently, antibiotic selection pressure. 
In this retrospective cohort study, we aimed to evaluate whether time to influenza 
diagnosis in patients with severe influenza is associated with the duration of antibiotic 
therapy.
Methods: We retrospectively included all hospitalized patients >16 years who tested 
positive for influenza A or B by polymerase chain reaction during influenza seasons 
2013/2014 or 2014/2015 at the University Hospital Zurich. The primary aim was to 
assess the association between timing of laboratory- confirmed influenza diagnosis 
and duration of antibiotic therapy. Secondary outcomes were length of hospital stay, 
duration of isolation precautions, and mortality. Early diagnosis was defined as labora-
tory confirmation on the day of or the day after hospital admission or symptom onset.
Results: A total of 126 patients were included (median age 57 years). Timing of influ-
enza diagnosis was not associated with the duration of antibiotic treatment, the dura-
tion of isolation precautions, or mortality. Early influenza was associated with reduced 
length of hospital stay (median 7 vs 9 days [P=.014]) in patients with community- 
acquired influenza.
Conclusions: Although the duration of antibiotic therapy and mortality were found 
unaffected by early influenza diagnosis, our data indicate that it is linked with a reduc-
tion in the length of hospitalization in patients with community- acquired influenza. 
This highlights a need to also fully understand the effect of time to diagnosis of bacte-
rial pathogens on antibiotic prescribing patterns in order to exploit the potential of 
early influenza diagnosis in patient care.
K E Y W O R D S
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1  | INTRODUCTION
Unspecific symptoms hamper influenza diagnosis based on clinical 
case presentation alone and differential diagnoses can be quite di-
verse, misinterpreting influenza infections as common cold, bacterial 
pneumonia or even non- infectious causes of fever.1,2 Although the 
likelihood of influenza is increased during winter season in patients 
with cough and fever,1,3,4 these predictors do not enable physicians to 
differentiate adequately between the various differential diagnoses.
Due to these unspecific and often misleading symptoms and po-
tentially severe complications, hospitalized patients with suspected or 
confirmed influenza diagnosis often receive antibiotic treatment.5,6 
Recommendations are to base influenza treatment on neuraminidase 
inhibitors together with symptomatic therapy and to use antibiotics 
only in severe cases or patients with high risks.7-9 In severe cases, an 
antibiotic agent active against Staphylococcus aureus is recommended, 
as staphylococcal pneumonia is known to be frequently associated 
with influenza.10 Interestingly, even though early influenza treatment 
with neuraminidase inhibitors was previously shown to be associated 
with shorter duration and reduced severity of illness, a faster resolu-
tion of fever, and a faster return to normal health and activity,11,12 only 
1.6% of patients with influenza- like symptoms in season 2014/2015 
were treated with neuraminidase inhibitors in Switzerland, and even 
less (0.4%) in 2013/2014.13 This management strategy, however, 
might also be influenced by study results that show only moderate 
benefit of neuraminidase inhibitors in reducing influenza symptoms in 
healthy outpatients and the lack of controlled clinical trials supporting 
a beneficial effect on severe outcomes in hospitalized patients despite 
a growing body of evidence from observational studies.14-17
A recent survey highlights that up to date, antiviral substances are 
underutilized and antibiotics overused in influenza patients.5 Despite 
the fact that in hospitalized adults with acute respiratory illness during 
winter season, viral infection seems to be more likely than bacterial,6 
patients often receive antibiotic treatment despite a diagnosis of re-
spiratory virus infection.18
More rapid influenza diagnosis may thus help streamline anti- 
infective treatment and reduce antibiotic consumption. As antibiotic 
overuse is associated with emergence of antibiotic resistance,19 rapid 
influenza diagnosis may therefore reduce antibiotic selection pres-
sure, resistance development, and support appropriate treatment. 
Consequently, rapid diagnosis of influenza has previously been shown 
to help reduce the use of antibiotics in adult outpatients20 and was 
shown to reduce the duration of antibiotic therapy, the amount of pre-
scription, and the length of hospital stay in children.21,22 Recent studies 
suggested a general benefit of hospitalized patients from early influ-
enza diagnosis by reducing the need for extended care after hospital 
discharge in older adults,23 mortality,24 and the risk of lower respira-
tory tract complications.25 Oosterheert et al. and Shiley et al. reported 
that viral respiratory tract diagnosis per se does not impact the use 
and duration of antibiotic treatment in hospitalized adults.18,26 In con-
trast, Rogers et al. showed that rapid influenza diagnosis did decrease 
duration of antibiotic use, length of hospitalization, and  duration of 
isolation in children admitted with respiratory symptoms.21
To clarify and validate the benefits of early diagnosis, we aimed to 
determine whether rapid laboratory confirmation of influenza infection 
in hospitalized adults reduced the duration of antibiotic therapy in a ret-
rospective cohort study of adults with influenza diagnosis hospitalized 
at the University Hospital Zurich, Switzerland, in seasons 2013/2014 
and 2014/2015. Secondary aims of our study were the analysis of the 
association between timeliness of influenza diagnosis, length of hos-
pital stay, duration of isolation precautions, and in- hospital mortality.
2  | MATERIALS AND METHODS
2.1 | Study setting, design, and procedures
We performed a single- center retrospective cohort study of hospitalized 
patients with laboratory- confirmed influenza diagnosis at the University 
Hospital Zurich over the 2013/2014 and 2014/2015 influenza seasons, 
defined as the time between the first and the last positive influenza test 
result in our institution in the time period between October 1 and April 
30. The University Hospital Zurich is a 900- bed university- affiliated ter-
tiary care center that covers all specialties except orthopedic surgery 
and pediatrics. It serves a population of 400 000 inhabitants for primary 
and 1 443 000 for tertiary care. Approximately 540 000 outpatients 
and 38 000 inpatients receive medical treatment each year.27-29
Our study retrospectively included all hospitalized and consenting 
patients greater than 16 years of age with influenza A or B infection con-
firmed by polymerase chain reaction (PCR)30 from respiratory specimens 
(nasopharyngeal swab or broncho- alveolar lavage) in influenza seasons 
2013/2014 and 2014/2015. Patients were identified from the infection 
control database, where all patients with suspected and confirmed in-
fluenza diagnosis are recorded. Clinical data (including baseline patient 
characteristics, living situation, influenza- like symptoms, vital signs and 
clinical findings upon admission or symptom onset, admission diagnoses, 
laboratory sampling, and disease treatment details) were then extracted 
from electronic medical records with the use of a standardized ques-
tionnaire and collected in an electronic database (Microsoft Access®, 
Version 14.0.7151.5001, 2010, Microsoft Corporation, Redmond, WA, 
USA). The pneumonia severity index (PSI),31 the Charlson comorbidity 
index,32 and the CURB- 65 Score31 were used to classify the severity 
of respiratory disease. “Generalized weakness” was defined as feeling 
weaker than before onset of symptoms.
2.2 | Definitions
2.2.1 | Predictor variable
The main predictor variable was the duration between symptom onset 
or hospital admission (whichever occurred first) and laboratory confir-
mation of influenza. Early influenza diagnosis was defined as labora-
tory confirmation on the day of or the day after hospital admission in 
patients with community- acquired influenza infection and the day of 
or the day after symptom onset in patients with nosocomial influenza 
infection, respectively. Nosocomial influenza was defined as occur-
rence of the first symptoms after admission to the hospital.
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2.2.2 | Outcome variables
Duration of antibiotic therapy was the primary outcome variable of 
interest. To estimate the duration of antibiotic therapy, all antimi-
crobials with antibacterial activity were included if treatment was 
initiated after the first symptom and stopped after laboratory con-
firmation of influenza infection. The variable beta- lactam antibiotics 
was divided into a broad- spectrum group with (including piperacillin, 
cefepime, ceftazidime, meropenem, and imipenem) and a narrow- 
spectrum group without (including penicillin, amoxicillin, amoxicillin/
clavulanic acid, cefuroxime, cefotaxime, ceftriaxone, ertapenem) an-
tipseudomonal activity.
Secondary outcomes were length of hospital stay, duration of 
isolation precautions and in- hospital mortality. Length of stay was 
defined as time between admission and discharge. Associations with 
length of hospital stay were analyzed for patients with community- 
acquired influenza infection only.
2.3 | Statistical analysis
Categorical data were tested for differences using Fisher exact tests, 
whereas continuous variables were tested using Wilcoxon rank sum 
tests or the Student’s t test, as appropriate. Cox regression analysis 
was used to detect differences in length of antibiotic therapy and 
length of hospital stay in patients with early as compared to late in-
fluenza diagnosis. Multivariable logistic regression analysis was used 
to determine differences in mortality. Potential confounders among 
patient characteristics with P-values <.05 in univariable analyses were 
considered for inclusion in multivariable models based on clinical judg-
ment, with final models representing those that best balanced parsi-
mony and fit. The limited number of outcomes was factored in when 
building the models to prevent overfitting.33 Data were analyzed using 
Stata ® version 13.1 (Stata Corporation, College Station, TX, USA). 
Two- tailed P- values <.05 were considered statistically significant.
2.4 | Ethics
The research was conducted in accordance with the Declaration 
of Helsinki and national and institutional standards. The study was 
reviewed and approved by the ethics committee of the Canton of 
Zurich (BASEC- Nr.: PB_2016- 00182). A general consent was given 
by the ethics committee for all patients hospitalized before January 
1, 2014, and for deceased patients, tourists, or patients who could 
not be contacted by mail or phone. Informed consent was obtained 
from all patients that were hospitalized with influenza at or after 
January 1, 2014.
3  | RESULTS
In total, 126 consenting patients with positive influenza PCR could be 
included in the study cohort. Fifty- three (42%) were diagnosed with 
influenza on the day of or the day after admission or symptom onset 
(early diagnosis group), respectively. Patient characteristics and out-
comes are shown in Tables 1 and 2 and S1.
Twenty- nine (23%) patients acquired influenza through nosocomial 
infection. Nosocomial influenza occurred after a median (range) of 8 
(1- 45) days of hospitalization. Primary admission diagnoses of these 
29 patients were cardiological (11 [37.9%] patients), hematological (6 
[20.7%]), gastrointestinal (5 [17.2%]) and other (7 [24.1%]) disorders. 
Patients with nosocomial influenza were older (median [range] age: 65 
[36- 93] years vs 58 [16- 86] years, P=.016) and had a higher Charlson 
comorbidity index (median [range] 5 [1- 9] vs 4 [0- 12], P=.019) and a 
higher PSI (median [range] 97 [47- 197] vs 87 [9- 222], P=.024) than pa-
tients with community- acquired influenza. In addition, they were more 
likely to exhibit fatigue (6 [20.7%] patients vs 3 [3.1%] patients, P=.005), 
had lower leukocyte counts (median [range] 5.47 [0.06- 24.69] G/L vs 
7.01 [0.03- 32.54] G/L, P=.042), and lower neutrophil counts upon first 
symptom onset (median [range] 3.71 [0.01- 14.01] G/L vs 5.18 [0.01- 
30.22] G/L, P=.045) than patients with community- acquired influenza 
on admission, but had higher maximum C- reactive protein values (me-
dian [range] 210 [27- 484] mg/L vs 103 [4.1- 536] mg/L, P=.018).
According to univariable analysis, patients with delayed influenza di-
agnosis had lower total neutrophil counts (P=.006), lower total leukocyte 
counts (P=.008), lower diastolic blood pressure on admission/symptom 
onset (P=.045), and were more likely to have acquired influenza infection 
nosocomially (P=.032) than patients with early influenza diagnosis.
3.1 | Duration of antibiotic therapy
Ninety- five of 126 patients (75.4%) received antibiotic therapy, 38 of 
53 (71.7%) of the early influenza diagnosis group, and 57 of 73 (78.1%) 
of the late influenza diagnosis group (P=.53). The median (range) dura-
tion of antibiotic therapy was 5 (0- 45) days in the early and 7 (0- 57) 
days in the late diagnosis group. Multivariable Cox regression analysis 
did not show a difference in the duration of antibiotic therapy (ad-
justed hazard ratio (HR): 2.4, 95% confidence interval (CI): 0.86- 6.70, 
P=.09; unadjusted HR: 0.89, 95% CI: 0.59- 1.34) between the early 
and late influenza diagnosis group after adjustment for generalized 
weakness, bilateral vs unilateral chest X- ray findings, and treatment 
with beta- lactam antibiotics with antipseudomonal activity (Figure 1). 
Generalized weakness on admission/symptom onset (P=.023) and uni-
lateral vs bilateral chest X- ray findings (P=.023) were independently 
associated with a shorter duration of antibiotic therapy.
3.2 | In- hospital mortality
Nine of 126 patients (7.1%) died during hospitalization. Late influenza 
diagnosis was not associated with in- hospital death in univariable logis-
tic regression analysis (odds ratio [OR]: 1.50, 95% CI: 0.36- 6.26, P=.58) 
(Table 3).
3.3 | Length of hospital stay
Ninety- seven of 126 (77.0%) influenza infections were community- 
acquired, 46 of 53 (86.8%) in the early diagnosis group and 51 of 
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73 (69.9%) in the late diagnosis group (P=.032). In multivariable Cox 
regression analysis of the subgroup with community- acquired infec-
tion, the duration of hospitalization was shorter in patients with early 
influenza diagnosis (adjusted HR: 0.51, 95% CI: 0.30- 0.88, P=.014; 
unadjusted HR: 0.70, 95% CI: 0.47- 1.06; Figure 2) after adjustment 
for C- reactive protein level at admission, isolation precautions, and 
treatment with beta- lactam antibiotics with antipseudomonal activity.
3.4 | Isolation precautions
Droplet precautions were initiated in 119 (94.4%) patients, 51 of 53 
(96.2%) in the early influenza diagnosis group, and 68 of 73 (93.2%) 
in the late diagnosis group (P=.70). Most (84.9%) patients were only 
isolated after influenza diagnosis. The timing of influenza diagnosis 
was not associated with the duration of isolation precautions (P=.17).
TABLE  1 Patient characteristics in a retrospective cohort of 126 hospitalized patients with laboratory- confirmed influenza diagnosis during 
influenza seasons 2013/2014 and 2014/2015
Characteristic
Early influenza 
diagnosis (n=53)
Late influenza 
diagnosis (n=73) P- value
Age, years, median (range) 58 (21- 93) 61 (16- 92) .33
Male sex, n (%) 28 (52.8) 38 (52.1) 1.00
Symptoms upon influenza diagnosis
Fever, n (%) 37 (69.8) 45 (61.6) .45
Cough, n (%) 37 (69.8) 57 (78.1) .31
Dyspnea, n (%) 20 (37.7) 24 (32.9) .58
Rhinitis, n (%) 12 (22.6) 10 (13.7) .24
Laryngitis, n (%) 9 (17.0) 19 (26.0) .28
Headache, n (%) 9 (17.0) 17 (23.3) .51
Generalized weakness, n (%) 8 (15.1) 3 (4.1) .05
Shivering, n (%) 7 (13.2) 13 (17.8) .62
Myalgia or arthralgia, n (%) 7 (13.2) 8 (11.0) .78
Vomiting or nausea, n (%) 5 (9.4) 7 (9.6) 1.00
Fatigue, n (%) 4 (7.6) 5 (6.8) 1.00
Chest pain, n (%) 3 (5.7) 2 (2.7) .65
Flank pain, n (%) 1 (1.9) 2 (2.7) 1.00
Back pain, n (%) 1 (1.9) 2 (2.7) 1.00
Diarrhea, n (%) 1 (1.9) 8 (11.0) .08
Temperature
Admission or first symptom, °C, median (range) 38.6 (38- 40) 38.6 (38- 40.4) .62
Maximum, °C, median (range) 39.1 (38- 40.1) 38.8 (38- 40.9) .82
Blood pressure on admission or first symptom
Systolic, mm Hg, median (range) 131 (53- 220) 120 (68- 168) .17
Diastolic, mm Hg, median (range) 77 (40- 103) 67 (35- 120) .045
Total leukocyte count
Admission or first symptom, G/L, median (range) 7.52 (0.6- 24.69) 5.92 (0.3- 32.54) .008
Maximum, G/L, median (range) 9.85 (0.98- 28.18) 8.92 (1.13- 68.44) .36
Total lymphocyte count
Admission or first symptom, G/L, median (range) 0.62 (0.03- 4.83) 0.62 (0.02- 2.65) .78
Maximum, median G/L (range) 1.65 (0.27- 4.96) 1.64 (0.25- 11.84) .71
Neutrophil count
Admission or first symptom, G/L, median (range) 5.67 (0.01- 18.83) 4.25 (0.01- 30.22) .006
Maximum, G/L, median (range) 7.39 (0.33- 24.03) 6.94 (0.18- 62.11) .42
C- reactive protein (mg/L)
Admission or first symptom, mg/L, median (range) 55 (3.8- 440) 59.5 (0.3- 536) .98
Maximum, mg/L, median (range) 98 (12- 440) 138 (4.1- 536) .42
Charlson comorbidity index on admission or first symptom, median (range) 4 (0- 12) 5 (0- 12) .08
(Continued)
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4  | DISCUSSION
Influenza- like symptoms are common reasons for outpatient visits 
during influenza seasons. Records refer to approximately 2500 vis-
its per 100 000 inhabitants per season in Switzerland over the last 
10 years.13 The 2014/2015 influenza season was comparatively se-
vere, with around 3400 consultations per 100 000 inhabitants, and 
four times more patients with an influenza diagnosis were hospitalized 
in the 2014/2015 season (4709 [0.8%] as compared to an average of 
1173 of hospitalizations per season in the previous 4 years).13 Overall, 
influenza accounts for 1.5% of all hospitalizations due to respiratory 
diseases in Switzerland per year.34 In comparison, around one million 
patients are hospitalized with primary pneumonia or influenza in the 
United States annually, representing 12.4% of the primary respiratory 
and circulatory hospitalizations.35
In a retrospective cohort study of hospitalized patients with in-
fluenza infection during the 2013/2014 and 2014/2015 influenza 
seasons in a tertiary care university- affiliated hospital in Zurich, 
Switzerland, we found that rapid influenza diagnosis was not asso-
ciated with a reduction in the duration of antibiotic use, nor with a 
difference in mortality. However, length of hospital stay was shown 
to be shorter in patients with community- acquired influenza infection 
and early influenza diagnosis. The proportion of isolation precautions 
and the duration of isolation were not different between patients with 
early and late influenza diagnosis, and only a small proportion of pa-
tients was preemptively put under isolation precautions.
We hypothesized that early diagnosis would reduce antibiotic use 
and antibiotic treatment duration in hospitalized patients with influ-
enza diagnosis, as viral respiratory infections normally do not require 
antibiotic therapy. This hypothesis was supported by Jeong et al., who 
showed a reduction of antibiotic prescriptions in outpatients with 
flu- like symptoms after introduction of an influenza virus rapid anti-
gen test in the emergency department.20 Furthermore, Rogers et al. 
demonstrated that rapid influenza detection reduces the use of antibi-
otics in hospitalized children.21 Our study, however, could not confirm 
such an effect on the duration of antibiotic therapy. Presumably, this 
was due to the severity of illness in our inpatient population. In Jeong 
et al.’s study, the patients were not hospitalized, and the study of 
Rogers et al. was limited to children, which normally do not have many 
comorbidities. Our study, on the other hand, included hospitalized and 
mostly comorbid patients, and antibiotic therapy in these patients is in 
line with current recommendations to empirically treat for presumed 
superinfection by bacterial pathogens.36,37
Despite the fact that there is growing evidence that early anti-
viral treatment may lower influenza- associated mortality in hospital-
ized patients,24 only a small proportion of patients of our cohort were 
empirically treated with neuraminidase inhibitors, and we could not 
detect a difference in antiviral treatment patterns between patients 
with early and late influenza diagnosis. Less than 60% of all patients 
with severe influenza diagnosis received appropriate treatment with 
neuraminidase inhibitors, indicating a need for improvement of phy-
sicians’ prescribing behaviors. Recent findings suggest that the initia-
tion of antiviral treatment after even more than 48 hours of symptom 
onset in patients with severe influenza is associated with improved 
survival.17
Low mortality rates and thus lack of statistical power may have 
contributed to the failure of our study to detect any association be-
tween time of diagnosis and mortality. Nevertheless, statistical power 
was sufficient to confirm known predictors of in- hospital death, such 
as Charlson comorbidity index, ICU admission, the use of broad- 
spectrum antibiotics, and the need of mechanical ventilation.
The association between early influenza diagnosis and a reduced 
length of hospital stay is in line with the findings by Rogers et al.21 
and Chaves et al.23,38 The reasons for this finding remain unclear, al-
though explanations could be a doctor’s delay in unclear or more se-
vere cases without typical signs and symptoms of influenza infection 
Characteristic
Early influenza 
diagnosis (n=53)
Late influenza 
diagnosis (n=73) P- value
Pneumonia severity index on admission or first symptom, median (range) 89 (24- 222) 88 (9- 197) .43
CURB- 65 Score on admission or first symptom, median (range) 1 (0- 5) 1 (0- 4) .38
Admission diagnosis .00
Pneumonia, n (%) 12 (22.6) 7 (9.5) <.001
Influenza, n (%) 4 (7.6) 1 (1.4)
Flu- like illness, n (%) 10 (18.9) 2 (2.7)
Asthma exacerbation, n (%) 0 (0) 1 (1.4)
COPD exacerbation, n (%) 4 (7.6) 3 (4.1)
Exacerbation of cystic fibrosis, n (%) 2 (3.8) 0 (0)
Sepsis/SIRS, n (%) 6 (11.3) 18 (24.7)
Bronchitis, n (%) 1 (1.9) 0 (0)
Other, n (%) 14 (26.4) 41 (56.2)
Community- acquired infection, n (%) 46 (86.8) 51 (69.9) .032
COPD, chronic obstructive pulmonary disease.
TABLE  1  (Continued)
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or late initiation of antiretroviral treatment resulting in increased 
duration of hospitalization. Other studies demonstrated that early 
treatment is associated with shorter duration and alleviation of symp-
toms,11,39 and a reduction of extended care after hospitalization.23,38 
Our study, however, in which antiviral use was low, is not able to 
confirm or rebut any of these findings.
Our study failed to demonstrate an effect of early diagnosis on the 
duration of isolation precautions. Even though our study population 
Outcome
Early influenza 
diagnosis (n=53)
Late influenza 
diagnosis (n=73) P- value
Duration of antibiotic therapy, days, median 
(range)
5 (0- 45) 7 (0- 57) .27
Any antibiotic therapy, n (%) 38 (71.7) 57 (78.1) .53
Length of hospital stay, days, median (range) 7 (2- 58) 9 (3- 95) .058
In- hospital death, n (%) 3 (5.7) 6 (8.2) .73
Isolation precautions
Droplet precautions, n (%) 51 (96.2) 68 (93.2) .7
Preemptive isolation after sampling, n (%) 8 (15.1) 4 (5.5) .17
Isolation after influenza diagnosis, n (%) 43 (81.1) 64 (87.7)
No isolation, n (%) 2 (3.8) 5 (6.8)
Duration of isolation precautions, days, 
median (range)
6 (1- 23) 8 (2- 39) .29
Antibiotic therapy
Narrow- spectrum beta- lactam, n (%) 21 (39.6) 14 (19.2) .015
Antipseudomonal beta- lactam, n (%) 17 (32.1) 31 (42.5) .27
Macrolide 19 (35.9) 7 (9.6) .001
Fluoroquinolone 2 (3.8) 12 (16.4) .041
Antiviral therapy
Any antiviral therapy 36 (67.9) 39 (53.4) .14
Preemptive treatment, n (%) 9 (17.0) 14 (19.2) .82
Initiation after influenza diagnosis, n (%) 27 (50.9) 25 (34.3) .07
Treatment duration, days, median (range) 7 (1- 54) 7 (2- 24) .43
ICU, intensive care unit.
TABLE  2 Outcomes of hospitalized 
patients with laboratory- confirmed 
influenza diagnosis during influenza 
seasons 2013/2014 and 2014/2015
TABLE  3 Univariable analysis of risk factors for in- hospital death
Risk factor Survivors (n=117) Deaths (n=9) P- valuea
Odds ratio (95% 
confidence interval)b
Early influenza diagnosis, n (%) 50 (42.7) 3 (33.3) .73 1.50 (0.36- 6.26)
Community- acquired influenza infection, n (%) 91 (77.8) 6 (66.7) .43 1.75 (0.41- 7.48)
ICU admission, n (%) 34 (29.1) 7 (77.8) .005 8.54 (1.69- 43.23)
Mechanical ventilation, n (%) 16 (13.7) 6 (66.7) .001 12.63 (2.87- 55.62)
Charlson comorbidity index, median (range) 4 (0- 12) 6 (3- 12) .020 1.32 (1.05- 1.66)
CURB- 65 score, median (range) 1 (0- 4) 1 (0- 5) .047 1.94 (1.16- 3.23)
Pneumonia severity index, median (range) 88 (9- 175) 123 (71- 222) .017 1.93 (1.01- 1.05)
C- reactive protein
Admission, mg/L, median (range) 52 (2.6- 440) 113.5 (0.3- 536) .019 1.01 (1.00- 1.01)
Maximum, mg/L, median (range) 109 (4.1- 484) 250 (27- 536) .015 1.01 (1.00- 1.01)
Maximum total neutrophil count, G/L, median (range) 6.9 (0.18- 62.11) 19 (2.78- 37.14) .036 1.07 (1.02- 1.13)
Diastolic blood pressure on admission or first symptom, mm Hg, 
median (range)
73 (35- 120) 54 (39- 67) <.001 0.91 (0.86- 0.96)
aAccording to Fisher exact tests or Wilcoxon rank sum tests, as appropriate.
bPer unit increase (for continuous variables in univariable logistic regression analysis).
ICU, intensive care unit.
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is not suitable for determining the effect of early diagnosis on days of 
isolation in patients with suspected—rather than confirmed—influenza 
diagnosis, such an effect may be small in our setting as preemptive 
isolation precautions were only taken in a small fraction of patients 
with influenza diagnosis.
Our study has several limitations. First, the findings of our study 
may not be generalizable to other settings. The University Hospital 
Zurich is a tertiary care referral center where, because of its many 
highly specialized departments, many patients with severe comorbid-
ities, such as lung and heart transplant recipients, or oncological pa-
tients receive treatment. The patients included in this study may thus 
not represent a cohort of hospitalized influenza patients as seen in 
other hospitals. Nevertheless, our patient population represents those 
at highest risk for severe influenza complications and therefore is of 
particular interest. Our findings may also not be translated to other 
influenza seasons or other regions in the same influenza seasons due 
to antigenic drift and changes in predominant influenza strains over 
time and even between geographically distinct settings. Second, our 
observations are only applicable to hospitalized adults with severe 
influenza; they cannot be extrapolated to adult outpatients with mild 
influenza or children. Early diagnosis might help optimize treatment 
and influence antibiotic selection pressure in these populations, as 
shown by others.20-25,38 Last, the interpretation of our findings is lim-
ited by the retrospective design of the study. Our results should be 
confirmed in the setting of a prospective study to eliminate bias.
In conclusion, we were able to demonstrate that diagnosis on 
the day of or the day after admission in hospitalized patients with 
community- acquired influenza infection is associated with shorter 
hospitalization. In contrast, timely diagnosis did not influence the du-
ration of antibiotic therapy, the duration of isolation precautions, or 
mortality in hospitalized patients with influenza. Physicians should 
consider early testing for influenza in patients with respiratory symp-
toms as this may facilitate earlier discharge and to re- assess the need 
for antibiotic treatment. Further research should focus on the time-
liness of diagnosis of not only influenza but also other respiratory 
pathogens and its influence on antibiotic use for situations where viral 
respiratory pathogens in the absence of bacterial superinfections are 
detected.33
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